SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy Inc. is trending as community debates the potential impact of earnings on the stock, especially its correlation to Bitcoin's price movements. Discussions include speculation on a possible short squeeze above a certain price point and its potential to trigger a gamma event, while some traders are pointing out that the company's market cap far exceeds its revenue. Amidst volatile overnight trading, the stock is being discussed in relation to its potential S&P 500 inclusion.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending after a strong earnings report driven by AWS and advertising growth, leading to significant after-hours gains. The community is discussing potential upgrades and a possible run to new all-time highs, while also analyzing the impact of the earnings on the broader market and the tech sector. Some are cautious, anticipating a sell-off like Google experienced, while others are optimistic about Amazon's potential in AI and cloud services.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's earnings are driving mixed sentiments, with initial reactions focusing on strong holiday quarter guidance despite some concerns about iPhone sales and revenue in China. Community discussions revolve around the stock's valuation, potential for growth, and whether the post-earnings gains are sustainable. Some traders are eyeing short-term opportunities, while others maintain a long-term bullish outlook on the tech giant.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as the community discusses potential buyout offers following competitor acquisitions in the obesity drug space, especially with upcoming presentations at ObesityWeek. Community talking points include speculation on potential acquirers and the value of VKTX's pipeline, particularly its oral and injectable GLP-1/GIP therapies, relative to recent deals. Bullish sentiment is fueled by analysts initiating coverage with buy ratings and high price targets.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as the community debates its future after a significant dip following earnings, despite strong revenue growth; conversation centers on increased AI spending and a one-time tax charge impacting EPS.  Bulls see a buying opportunity and anticipate a swift recovery, while bears express concerns about capital expenditure and potential market manipulation. A massive bond sale is being interpreted by some as a sign of institutional confidence.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is trending as investors discuss its potential for a short squeeze, fueled by high short interest and upcoming earnings. Bullish sentiment surrounds the company's position to capitalize on future housing market improvements and potential benefits from AI integration, while some bears express concerns about debt and integration challenges.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest recent earnings and future growth prospects for IBSRELA and XPHOZAH, particularly as a new pipeline asset is being developed. Community members are actively discussing revenue potential, pipeline optionality, and patent protection. The stock's movement is also influenced by broader discussions around the renal and biopharmaceutical sectors.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid speculation of a potential acquisition, with SpaceX named as a possible suitor, driving community discussion around the implications for Apple, a key partner.  Investors are weighing the potential value of Globalstar's spectrum and existing partnerships, especially as earnings approach and strategic scenarios, such as a bidding war, are considered.  The surge in interest reflects the broader race for satellite communication dominance and the strategic importance of spectrum assets.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power Inc - Ordinary Shares - Class A

Solid Power ($SLDP) is trending after announcing a joint evaluation agreement with Samsung and BMW to advance all-solid-state battery technology, sparking excitement about its potential in the EV sector. The community is actively discussing the implications of this partnership, with some speculating about warrant values and future announcements. While some compare Solid Power to competitors like QuantumScape, bullish sentiment is building around the company's progress and partnerships.

UP AND TO THE RIGHT

UPRIGHT CRYPTO is gaining attention for its consistent chart patterns and strong community, with many highlighting its disciplined approach and focus on long-term growth. The community emphasizes patience and stability, suggesting that the token is gearing up for a significant move. Discussions revolve around its organic rise and potential for substantial gains as momentum builds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>A takeover or a large partnership was reportedly on the table for the company.</li><li>According to a report from Seeking Alpha, citing Stat News, the nature of the potential agreement, while unclear, is one of “significant scope.”&nbsp;</li><li>Moderna has been seeking to expand its portfolio since COVID-19 infections dropped globally. &nbsp;</li></ul>Shares of Moderna (MRNA) jumped 17% on Thursday afternoon following reports that the company held talks with at least one large drugmaker.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/news/4511489-moderna-gains-on-report-it-held-talks-with-at-least-one-large-drugmaker">report</a> from Seeking Alpha, citing Stat News, a takeover or a large partnership was being considered for the company. The nature of the potential agreement, while unclear, is one of “significant scope,” the report added. &nbsp;<h2 class="st-heading-2">Moderna’s Weakening Sales</h2>In August, the vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end of the range.For the second quarter, the company reported revenues of $142 million, down from the $241 million reported in the corresponding quarter of 2024. The company attributed the revenue drop to lower COVID-19 vaccine sales. It noted that its demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons, due to the seasonal nature of the infection.Sales of Moderna’s COVID-19 vaccine came in at $114 million in the three months through the end of June, while its Respiratory Syncytial Virus vaccine sales were negligible.The company has been seeking to expand its portfolio since COVID-19 infections dropped globally from their peak in the early 2020s. The company hit a peak yearly revenue of $19.3 billion in 2022, when COVID-19 &nbsp;infections were high, which then dropped to $3.2 billion in 2024. The shares have borne the brunt, dropping over 57% in the past five years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user sounded cautious about the company’s upcoming earnings.<stembedurl>https://stocktwits.com/Galba/message/634362215</stembedurl>Since the start of the year, the company’s shares have declined by approximately 30%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bmy-ceo-expects-cancer-drug-opdivo-to-drive-strong-sales-in-2025/cLG8bFRR3xp">BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Rallies On Reports Of Company Entering Talks With A Drugmaker For A Potential Deal

According to a report from Seeking Alpha, citing Stat News, Moderna has held talks with at least one large drugmaker. 

Equity

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

mRNA Vaccine For Birth Defects Didn't Work Well, Won't Be Continued: Moderna

mRNA Vaccine For Birth Defects Didn't Work Well, Won't Be Continued: Moderna Moderna - which has been around less than 10 years and 'somehow' convinced the government to mandate their mRNA jabs for...

Wall Street's top analyst calls for the week of October 20, 2024

Yahoo Finance looks at Wall Street's top analyst call for the week of October 20, 2024. 0:00 Ebay, Deckers Outdoor, Intel October 24, 2025 1:37 Tesla, Zions Bancorp, Moderna October 23, 2025 3:25...

Moderna (MRNA) Outperforms Broader Market: What You Need to Know

Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

<ul class="summary-bullets"><li>Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program.</li><li>The biotech will continue testing the vaccine in bone marrow transplant patients, where CMV reactivation can cause serious complications, and said no safety concerns were identified.</li><li>Moderna reaffirmed its 2025 guidance and breakeven goal for 2028, noting the vaccine was expected to be cash-flow negative that year.</li></ul>Moderna Inc. shares fell 4% in after-hours trading on Wednesday after the biotech company said its investigational cytomegalovirus (CMV) vaccine, mRNA-1647, failed to meet its primary efficacy endpoint in a late-stage trial.<h2 class="st-heading-2">Phase 3 Trial Misses Target</h2>The Phase 3 trial was designed to determine if the vaccine can prevent CMV infection among seronegative women aged 16-40. Moderna stated that the vaccine efficacy was substantially below the company's expectations and fell between 6 and 23% depending on the case definition used. The company will not continue the development of mRNA-1647 for the prevention of congenital CMV.“Today's announcement is disappointing for families and healthcare professionals who have been eagerly awaiting a CMV vaccine to prevent congenital CMV,” said CEO Stephane Bancel in a statement. “We will share full results with the scientific community in hopes that our learnings contribute to the continued pursuit of a CMV vaccine.”<h2 class="st-heading-2">Focus Shifts To Transplant Patients</h2>Moderna will further evaluate mRNA-1647 in a Phase 2 trial for bone marrow transplant recipients, who can experience serious complications when CMV is reactivated. The company said it will investigate the vaccine’s ability to suppress CMV reactivation in this high-risk population.The company said mRNA-1647 was well-tolerated with no safety concerns identified by the trial’s monitoring board.<h2 class="st-heading-2">No Impact On Financial Outlook</h2>Moderna said the setback is not expected to impact its 2025 financial guidance or its path to breakeven in 2028. The company had expected low revenue for the CMV vaccine in the near term before investments in the market and for the product to be cash-flow negative in 2028.<h2 class="st-heading-2">Stocktwits Users Debate Cash Burn, Oncology Focus After Vaccine Failure</h2>On Stocktwits, retail sentiment for Moderna was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img style="aspect-ratio:978/137;" src="https://news.stocktwits-cdn.com/mrna_ss_jpg_45aec4f522.webp" alt="mrna ss.jpg" width="978" height="137"><figcaption>MRNA sentiment and message volume as of October 22 | Source: Stocktwits</figcaption></figure>One user suggested the company’s decision to discontinue the CMV program might actually help reduce its cash burn, saying the move could allow Moderna to concentrate more effectively on its oncology pipeline.<stembedurl>https://stocktwits.com/pfh_investing/message/633326630</stembedurl>Another user expressed concern that the company’s spending remained unsustainable, describing its cash burn as “endless.”<stembedurl>https://stocktwits.com/KK_KK/message/633344767</stembedurl>A third bearish user took a harsher view, warning that the stock could fall below $5, after revealing they held two sold naked calls expiring this week.<stembedurl>https://stocktwits.com/georgeyann/message/633359261</stembedurl><a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> has declined 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn

The biotech will continue testing the vaccine in bone marrow transplant patients, where CMV reactivation can cause serious complications, and said no safety concerns were identified.

Market Wrap- Top Stocks: Tesla, Intuitive Surgical

The earnings season has sent the market into a scramble. Strong reports from major banks last week sent the market soaring, followed by Tuesday's estimate miss from Netflix and electric-vehicle...

Moderna (MRNA) Dips More Than Broader Market: What You Should Know

Moderna (MRNA) closed at $26.85 in the latest trading session, marking a -2.33% move from the prior day.

Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.

R&D spending now can have big payoffs later for companies

Just how long have people been saying you have to spend money to make money"?Historians maintain that this particular proverb goes all that way back to the Roman playwright Titus Maccius Plautus, who...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$28.39
Prev Close	$24.70
Open	$24.43
Dividend Yield	0.00%
50-Day Moving Average	$25.90
Beta	1.23
Avg. Volume	12.41M
PE Ratio	-3.74

52-Week High	$56.70
52-Week Low	$23.15
Market Capitalization	$10.99B
EPS (Annual)	-$9.27
Price to Book	1.16
Revenue Per Employee	$557,931.03
Enterprise Value/EBITDA	N/A

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc